Analyst Ratings For Dova Pharmaceuticals (NASDAQ:DOVA)
Today, Dova Pharmaceuticals (NASDAQ:DOVA) stock received an upgrade by Leerink Swann from Market Perform to Outperform.
There are 3 buy ratings on the stock.
The current consensus rating on Dova Pharmaceuticals (NASDAQ:DOVA) is Buy (Score: 3.00) with a consensus target price of $29.67 per share, a potential 32.15% upside.
Some recent analyst ratings include
- 9/26/2017-Leerink Swann Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 7/24/2017-J P Morgan Chase & Co initiated coverage with a Overweight rating.
- 7/24/2017-Jefferies Group LLC initiated coverage with a Buy rating.
- On 8/16/2017 Paul B Manning, Director, bought 25,870 with an average share price of $22.30 per share and the total transaction amounting to $576,901.00. View SEC Filing
- On 8/15/2017 Steven M Goldman, Director, bought 20,169 with an average share price of $22.23 per share and the total transaction amounting to $448,356.87. View SEC Filing
- On 7/5/2017 Alex Sapir, CEO, bought 20,100 with an average share price of $17.00 per share and the total transaction amounting to $341,700.00. View SEC Filing
- On 7/5/2017 Kevin Laliberte, VP, bought 6,200 with an average share price of $17.00 per share and the total transaction amounting to $105,400.00. View SEC Filing
- On 7/5/2017 Lee F Md Phd Allen, Insider, bought 3,500 with an average share price of $17.00 per share and the total transaction amounting to $59,500.00. View SEC Filing
- On 7/5/2017 Steven M Goldman, Director, bought 72,000 with an average share price of $17.94 per share and the total transaction amounting to $1,291,680.00. View SEC Filing
Recent Trading Activity for Dova Pharmaceuticals (NASDAQ:DOVA)
Shares of Dova Pharmaceuticals closed the previous trading session at with shares trading hands.
